Latham & Watkins represented Cochran in the case. In an historic ruling, the U.S. Supreme Court this morning held that Texas Accountant Michelle Cochran has the...
SEC v. Cochran
TELA Bio’s $45.125 Million Common Stock Public Offering
Goodwin Procter advised TELA Bio, while Latham & Watkins advised the underwriters on the offering. TELA Bio, Inc. has announced the pricing of its previously announced underwritten...
Immuneering’s $30 Million Common Shares Offering
Latham & Watkins represented Immuneering in the offering, while Sidley Austin represented the underwriters involved. Immuneering Corporation (Nasdaq: IMRX) announced the pricing of its underwritten offering...
Vaxcyte’s $500 Million Public Offering
Cooley advises Vaxcyte on the offering, and Latham & Watkins advises the underwriters. Vaxcyte, Inc. (Nasdaq: PCVX) has announced the pricing of an underwritten public offering...
Azora’s $13.5 Million Acquisition of Strategic Stake in Abatable
Latham & Watkins advised Azora on the deal. Azora announced its $13.5 million strategic minority stake in Abatable, a carbon procurement and market intelligence platform for the...
Take-Two Interactive Software’s $1 Billion Senior Notes Offering
Willkie Farr advised Take-Two, and Latham & Watkins advised the underwriters. Take-Two Interactive Software, Inc. closed its underwritten public offering of $1 billion aggregate principal amount...
TORL BioTherapeutics’ $158 Million Series B Financing Round
Crandon Law served as counsel to TORL BioTherapeutics, and Latham & Watkins served as counsel to Goldman, Sachs & Co. TORL BioTherapeutics LLC has announced its...
Merck’s Acquisition of Prometheus Biosciences
Paul, Weiss, Rifkind, Wharton & Garrison represented Merck, Latham & Watkins represented Prometheus, Skadden represented the financial advisors on the deal. Prometheus Biosciences, Inc. have entered...
Sanofi, AstraZeneca and Sobi’s Streamlining of Nirsevimab Contractual Arrangements
Latham & Watkins represented Sobi in the transaction. Sanofi has simplified its contractual arrangements relating to the development and commercialization of Beyfortus (nirsevimab) in the United...
Apex Group’s £40 Million Acquisition of MJ Hudson Businesses
Kirkland & Ellis advised Apex Group, and Walker Morris advised MJ Hudson. Apex Group Ltd. announced the planned acquisition of various operating businesses of MJ Hudson...
Chimera’s Joint Venture with Haeres Capital
Latham & Watkins advised Chimera Abu Dhabi on the deal. Chimera Abu Dhabi announced its joint venture with Haeres Capital to create ChimHaeres Investment Holding, an investment...
Summit Partners and Peugeot Invest’s Majority Growth Investment in Doctrine
Latham & Watkins advised Summit Partners on the deal. Doctrine announced a majority growth investment from Summit Partners and Peugeot Invest. The investment aims to support Doctrine,...